BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 11, 2010
View Archived Issues
Alexza Brings in $40M from Biovail Deal to Develop Inhaled Antipsychotic
Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today)
Read More
Mipomersen a Niche-Only Drug? Safety Drags Positive Phase III
Read More
Lysosomal Storage Disorder Gene Implicated in Stuttering
Read More
Daring 'TB' Different; Early Stage Aarden Working on PTP Drugs
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Financings Roundup
Read More